Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook

immune checkpoint inhibitors

  • You have access
    The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals
    Guus A.M.S. van Dongen, Wissam Beaino, Albert D. Windhorst, Gerben J.C. Zwezerijnen, Daniela E. Oprea-Lager, N. Harry Hendrikse, Cornelis van Kuijk, Ronald Boellaard, Marc C. Huisman and Danielle J. Vugts
    Journal of Nuclear Medicine April 1, 2021, 62 (4) 438-445; DOI: https://doi.org/10.2967/jnumed.119.239558
  • You have access
    Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non–Small Cell Lung Cancer
    Marc C. Huisman, Anna-Larissa N. Niemeijer, Albert D. Windhorst, Robert C. Schuit, David Leung, Wendy Hayes, Alex Poot, Idris Bahce, Teodora Radonic, Daniela E. Oprea-Lager, Otto S. Hoekstra, Erik Thunnissen, N. Harry Hendrikse, Egbert F. Smit, Adrianus J. de Langen and Ronald Boellaard
    Journal of Nuclear Medicine October 1, 2020, 61 (10) 1455-1460; DOI: https://doi.org/10.2967/jnumed.119.240895
  • You have access
    Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma
    Jaeyeon Choi, Wissam Beaino, Ronald J. Fecek, Kellsye P.L. Fabian, Charles M. Laymon, Brenda F. Kurland, Walter J. Storkus and Carolyn J. Anderson
    Journal of Nuclear Medicine December 1, 2018, 59 (12) 1843-1849; DOI: https://doi.org/10.2967/jnumed.118.209510
  • You have access
    Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma
    Jessie R. Nedrow, Anders Josefsson, Sunju Park, Sagar Ranka, Sanchita Roy and George Sgouros
    Journal of Nuclear Medicine October 1, 2017, 58 (10) 1560-1566; DOI: https://doi.org/10.2967/jnumed.117.193268
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire